🏛️ Verified NIH Record • Updated 2025-10-31
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (NCT05902988)
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Volastra Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Who can join: Review the eligibility criteria below.
Location: University of Southern California — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- University of Southern California — Los Angeles, California
- Hoag Memorial Hospital — Newport Beach, California
- University of Colorado Cancer Center — Aurora, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Kellogg Cancer Center — Evanston, Illinois
- Community Health Network — Indianapolis, Indiana
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- START Midwest — Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- The Christ Hospital — Cincinnati, Ohio
- Women & Infants Hospital — Providence, Rhode Island
- M.D. Anderson Cancer Center — Houston, Texas
- Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (646) 344-1248
Email: clinicaltrials@volastratx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.